Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS)

被引:12
|
作者
Selim, Mohamed Fouad [1 ]
Hussein, Adnan Fathey [2 ]
机构
[1] Zagazlg Univ, Dept Obstet & Gynecol, Zagazlg 44519, Egypt
[2] Minufyia Univ, Dept Cardiol, Shibin Al Kawm 15521, Egypt
关键词
Levonorgestrel-releasing intrauterine system; Endothelial dysfunction; Flow-mediated vasodilatation; FLOW-MEDIATED DILATION; LONG-TERM USERS; BRACHIAL-ARTERY; DEPENDENT VASODILATION; ORAL-CONTRACEPTIVES; POSTMENOPAUSAL WOMEN; ESTROGEN; PLASMA; RISK; PROGESTERONE;
D O I
10.1016/j.contraception.2012.12.008
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Oral levonorgestrel has been linked to increased cardiovascular risk, but currently, no information is available on the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on endothelial dysfunction. The objective of this study was to assess endothelial function in LNG-IUS users. Study Design: Sixty women underwent insertion of either an LNG-IUS (n=30) as study group or Copper-T intrauterine contraceptive device (TCu 380A intrauterine device) as control group (n=30). In the midluteal phase of menstrual cycle, endothelium-dependent flow-mediated dilatation (FMD) and endothelium-independent dilatation of brachial artery were studied before and after 3, 6 and 12 months of device insertion. We also assessed the correlation of FMD and serum concentrations of estradiol (E-2), progesterone (P) and LNG. Results: With LNG-IUS, there was a nonsignificant decrease in mean FMD of brachial artery (p>.05) compared with the control group at different time points of the study. Before LNG-IUS, reactive hyperemia caused an 8.3%+/- 1.3% increase in brachial artery diameter compared with 7.1%+/- 1.1%, 7.4%+/- 0.9% and 7.5%+/- 0.9% after 3, 6 and 12 months of LNG-IUS (p>.05). The mean +/- SD LNG plasma levels at 3, 6 and 12 months of LNG-IUS application were 228 87, 204 94 and 191 79 pg/mL, respectively. E2 levels were comparable in women of both studied groups. Mean P levels were significantly lower after LNG-IUS insertion compared with before device insertion and with the control group (p<.05) at all study visits. No correlation was found between LNG levels and FMD. Conclusions: A nonsignificant change detected in endothelial function in LNG-IUS indicates that it has no increased cardiovascular risk. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:396 / 403
页数:8
相关论文
共 50 条
  • [21] Levonorgestrel-Releasing Intrauterine System (LNG-IUS): Adherence to Pre-Insertion Recommendations. Are We Good at It?
    King, A.
    Patravali, N.
    [J]. AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2019, 59 : 31 - 31
  • [22] Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)-a multicentre prospective study
    Gemzell-Danielsson, K.
    Inki, P.
    Boubli, L.
    O'Flynn, M.
    Kunz, M.
    Heikinheimo, O.
    [J]. HUMAN REPRODUCTION, 2010, 25 (02) : 354 - 359
  • [23] Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil
    Valeria Bahamondes, M.
    de Lima, Yuri
    Teich, Vanessa
    Bahamondes, Luis
    Monteiro, Ilza
    [J]. CONTRACEPTION, 2012, 86 (03) : 244 - 250
  • [24] Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5mg) after abortion for unintended pregnancy
    Caruso, Salvatore
    Cianci, Stefano
    Vitale, Salvatore Giovanni
    Fava, Valentina
    Cutello, Silvia
    Cianci, Antonio
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2018, 23 (01): : 24 - 31
  • [25] Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS)
    Lessard, Tricia
    Simoes, Jose A.
    Discacciati, Michelle G.
    Hidalgo, Margarete
    Bahamondes, Luis
    [J]. CONTRACEPTION, 2008, 77 (01) : 30 - 33
  • [26] AN EVALUATION OF THE SIMULTANEOUS USE OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS, MIRENA®) COMBINED WITH ENDOMETRIAL ABLATION IN THE MANAGEMENT OF MENORRHAGIA
    Vaughan, D. A.
    Byrne, P.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : 154 - 154
  • [27] COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
    Lete, I
    Cristobal, I
    Febrer, L.
    Crespo, C.
    Hernandez, F. J.
    Arbat, A.
    Serrano, D.
    Brosa, M.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A423 - A423
  • [28] Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer
    Neven, Patrick
    Amant, Frederik
    Poppe, Willy
    Van den Broecke, Rudy
    [J]. FERTILITY AND STERILITY, 2009, 91 (04) : E5 - E5
  • [29] THE COST-EFFECTIVENESS OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS, MIRENA®) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING IN THE UNITED STATES
    Ganz, M.
    Shah, D.
    Gidwani, R.
    Filonenko, A.
    Su, W.
    Pocoski, J.
    Law, A.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A107 - A107
  • [30] Expulsion rate among users of two models of intrauterine devices (IUD), the Multiload 375 and the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena)
    Petta, Carlos A.
    Faundes, Daniel
    Bahamondes, Luis
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 143 (01) : 64 - 64